Abstract:Abstract Background The treatment of tuberous sclerosis complex (TSC) using mammalian target of rapamycin (mTOR) inhibitors is clinically promising. The aim of the present study was to evaluate the efficacy and safety of mTOR inhibitors for improving the clinical symptoms of TSC. Methods We performed a systematic search of major electronic databases (PubMed, EMBASE, Cochrane Library and WanFang, CNKI, and VIP databases) to identify randomized controlled trials (RCTs) and quasi-randomized studies from the date of database inception to November 2017; the Chinese Food and Drug Administration and clinicaltrials.gov were also searched for unpublished studies. The endpoints of the study were the tumor response rate and seizure frequency response rate (the proportion of patients achieving a ≥ 50% reduction relative to the baseline). Two researchers screened articles, assessed the risk of bias and extracted data independently. The included RCTs were analyzed using RevMan 5.3, which was provided by the Cochrane Collaboration. Results Compared with the placebo, mTOR inhibitors significantly reduced tumor volume in both angiomyolipoma (AML) (RR = 24.69, 95% CI = 3.51,173.41, P = 0.001) and subependymal giant cell astrocytoma (SEGA) (RR = 27.85, 95% CI = 1.74,444.82, P = 0.02). Compared with the placebo, mTOR inhibitors significantly reduced seizure frequency (RR = 2.12, 95% CI = 1.41,3.19, P = 0.0003). Regarding safety, compared with patients who did not receive mTOR inhibitors, those who did had a higher risk of suffering stomatitis (RR = 3.20, 95% CI = 1.49,6.86, P = 0.003). In contrast, patients who did and did not receive mTOR inhibitors experienced similar adverse events, such as upper respiratory tract infections (RR = 1.08, 95% CI = 0.81,1.45, P = 0.59) and nasopharyngitis (RR = 0.86, 95% CI = 0.60,1.21, P = 0.38). Conclusion In view of the efficacy and safety associated with tumor and seizure frequency in the TSC patients, mTOR inhibitors is a good therapeutic choice. Unlike the risks of upper respiratory tract infections and nasopharyngitis, mTOR inhibitors seem to increase the risk of stomatitis, mostly grade 1 and 2.

Modulation of TSC-mTOR Signaling on Immune Cells in Immunity and Autoimmunity.

[Research Advances in the Role of Mtor Signaling Pathway in Autism Spectrum Disorder].

Mtor Signaling in T Cell Immunity and Autoimmunity

TSC 1 Regulates the Balance Between Effector and Regulatory T Cells

mTORC1 and mTORC2 as regulators of cell metabolism in immunity

Regulatory Function of Phosphorylation and Ubiquitination on The TORC1 Signaling Pathway

Efficacy and Safety of Mtor Inhibitors (rapamycin and Its Analogues) for Tuberous Sclerosis Complex: a Meta-Analysis

AKT-mediated phosphorylation of TSC2 controls stimulus and tissue-specific mTORC1 signaling and organ growth

TSC1 controls macrophage polarization to prevent inflammatory disease

mTORC2: a multifaceted regulator of autophagy

mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment

Mtor Signaling: A Pivotal Player in Treg Cell Dysfunction in Systemic Lupus Erythematosus.

The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism

Tsc Tumour Suppressor Proteins Antagonize Amino-Acid–tor Signalling

Regulation of Hematopoietic Stem Cells Differentiation, Self-Renewal, and Quiescence Through the Mtor Signaling Pathway

Macrophage-Induced Tumor Angiogenesis is Regulated by the Tsc2-Mtor Pathway.

Regulation of Intrinsic and Bystander T Follicular Helper Cell Differentiation and Autoimmunity by Tsc1

TSC2 S1365A mutation potently regulates CD8+ T cell function and differentiation and improves adoptive cellular cancer therapy

The Genetics of Tuberous Sclerosis Complex and Related mTORopathies: Current Understanding and Future Directions

Disruption of Tsc1/2 Signaling Complex Reveals A Checkpoint Governing Thymic Cd4(+)Cd25(+)Foxp3(+), Regulatory T-Cell Development in Mice

Mtor-Dependent Upregulation of Xct Blocks Melanin Synthesis and Promotes Tumorigenesis